Abstract
Ustekinumab (Stelara®, Janssen-Cilag, Centocor Ortho) is a fully humanized IgG1k monoclonal antibody binding with high affinity to the p40 subunit shared by interleukin-12 (IL-12) and IL-23 heterodimeric cytokines, thus preventing their binding to the IL-12Rβ1 receptor expressed on the surface of immune cells and therefore neutralizing their biological activity. In December 2008, Health Canada authorized ustekinumab for the treatment of chronic moderate to severe plaque psoriasis (Ps) in adult patients suited for phototherapy or systemic therapy. EMEA granted first approval of ustekinumab in January 2009 for the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are intolerant or have a contraindication, or failed to respond to systemic therapies including cyclosporine, methotrexate, and PUVA. Following the initial submission in November 2007, approval from FDA was granted in September 2009 for adult (≥18 years) patients with Ps, who are candidates to phototherapy or systemic therapy. In December 2012, the sponsor requested both Agencies to extend the treatment to patients with active psoriasic arthritis (PsA). The request was accepted in September 2013 by both Agencies.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ustekinumab (Stelara®) SBD 114272 Health Canada, Dec 2008 (issued May 2009)
Ustekinumab (Stelara®) WC500058511 Assessment Report EMEA, Feb 2009
Ustekinumab (Stelara®) BLA 125261 Medical Review FDA, Sept 2009
Ustekinumab (Stelara®) Prescribing Information, Janssen, May 2013
Robertson MJ, Ritz J (1996) Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1:88–97
Torti DC, Feldman SR (2007) Interleukin-12, interleukin-23 and psoriasis: current prospects. J Am Acad Dermatol 57:1059–1068
Monteleone I, Pallone F, Monteleone G (2009) Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm. doi:10.1155/2009/297645
Becher B, Durell BG, Noelle RJ (2003) IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 112:1186–1191
Benson JM, Peritt D, Scallon BJ et al (2011) Discovery and mechanism of ustekinumab. A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 3:535–545
Tsuda K, Yamanaka K, Kondo M et al (2012) Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity. PLoS ONE 7:e51819. doi:10.1371/journal.pone.0051819
Kimball AB, Gordon KB, Fakharzadeh S et al (2012) Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 166:861–872
Lebwohl M, Leonardi C, Griffiths CEM et al (2011) Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 66:731–741
Yeilding N, Szapary P, Brodmerkel C et al (2012) Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives—an update. Ann NY Acad Sci 1263:1–2 (see also 1262:30–39, 2011)
Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665–1674
Croxtall JD (2012) Ustekinumab. A review of its use in the management of moderate to severe plaque psoriasis. Drugs 71:1773–1753
Gordon KB, Papp KA, Langley RG et al (2011) Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 66:742–751
Kimball AB, Papp KA, Wasfi Y et al (2012) Long-term efficacy in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. doi:10.1111/jdv.12046
Tsai T-F, Ho V, Song M et al (2012) The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. doi:10.1111/j.1365-2133.2012.11142.x
Young L, Czarnecki (2012) The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australasian J Dermatol 53:57–60
Rustin MHA (2012) Long-term safety of biologics in the treatment of moderate-to-severe psoriasis: review of current data. Br J Dermatol 167(s3):3–11
Ryan C, Leonardi CL, Krueger JG et al (2012) Association between biologic therapies for chronic plaque psoriasis and cardiovascular events. JAMA 306:864–871
Tzellos T, Kyrgidis A, Zouboulis CC (2012) Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. doi:10.1111/j.1468-3083.2012.04500.x
Tsai T-F, Ho J-C, Song M et al (2011) Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 63:154–163
Igarashi A, Kato T, Kato M et al (2012) Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. J Dermatol 39:242–252
Laws PM, Downs AM, Parslew R et al (2012) Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. Br J Dermatol 166:189–195
Navarro R, Vilarrasa E, Herranz P et al (2012) Safety and effectiveness of ustekinumab and anti-tumor necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C. A retrospective, multicentre study in a clinical setting. Br J Dermatol. doi:10.1111/bjd.12045
Viguier M, Pagès C, Aubin F et al (2012) Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol 167:417–423
Santos-Juanes J, Coto-Segura P, Mas-Vidal A et al (2010) Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol 162:1144–1146
Wang T-S, Tsai T-F (2011) Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol 38:1096–1099
Pernet C, Guillot B, Bessis D (2012) Eczematous drug eruption after ustekinumab treatment. Arch Dermatol 148:959–960
Becker JG, Mundi JP, Newlove T et al (2012) Development of linear bullous dermatosis in a patient with psoriasis taking ustekinumab. J Am Acad Dermatol. doi:org/10.1016/j.jaad.2011.11.955
McInnes IB, Kavanaugh A, Gottlieb AB et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780–789
Gottlieb A, Narang K (2013) Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskel Dis 5:277–285
Segal BM, Constantinescu CS, Raychaudhuri A et al (2008) Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7:796–804
Sandborn WJ, Gasink C, Gao L–L et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. NEJM 367:1519–1528
Guenova E, Teske A, Fehrenbacher B et al (2011) Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 147:1203–1205
Fahmy M, Ramamoorthy S, Hata T et al (2012) Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol 107:794–795
Gulliver WP, Jemec GBE, Baker KA (2011) Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 26:911–914
Balestri R, Bardazzi F, Antonucci A (2010) Should ustekinumab really be used as first-line biological therapy in pityriasis rubra pilaris? Br J Dermatol 163:896–897
Brezinski EA, Armstrong AW (2012) Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose-escalation, reduction, and interrupted biologic therapy. PLoS ONE 7:e33486, 1–10
Sterry W, van de Kerkhof P (2012) Is “class effect” relevant when assessing the benefit/risk profile of a biologic agent? J Eur Acad Dermatol Venereol 26(S5):9–16
Author information
Authors and Affiliations
Corresponding author
1 Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Tridente, G. (2014). Ustekinumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_39
Download citation
DOI: https://doi.org/10.1007/978-88-470-5313-7_39
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5312-0
Online ISBN: 978-88-470-5313-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)